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U.S. FEDERAL GENOMIC DATA RELEASE AND ACCESS POLICIES 
 
By: Jorge L. Contreras 
 
Introduction 
Researchers today have access to a vast aggregation of human and nonhuman genomic 
data, largely on an open access basis. According to the Joint Genome Institute’s Genomes OnLine 
Database (GOLD), data from more than 40,000 sequencing projects around the world, representing 
more than 375,000 different organisms, were publicly available to researchers as of July 2020.1 
The availability of this tremendous public resource is due, in large part, to the data release policies 
developed a quarter century ago, toward the beginning of the Human Genome Project (HGP), 
which have been carried forward, in modified form, to the present. These policies impose 
requirements on both the generators of data (typically the sequencing centers and other laboratories 
conducting genetic experiments) and the users of that data (i.e., researchers who download and/or 
use it).  This article, briefly outlines the history of such data release policies, particularly in the 
U.S. and with respect to human genomic data, and provides an overview of the obligations imposed 
on both data generators and data users. 
 
The Genomic Data Landscape 
The principal global databases for the deposit of genomic sequence data are GenBank, 
which is administered by the National Center for Biotechnology Information (NCBI) a division of 
the NIH’s National Library of Medicine (NLM), the European Molecular Biology Library (EMBL) 
in Hinxton, England, and the DNA Data Bank of Japan (DDBJ). NCBI also maintains the RefSeq 
database, which consolidates and annotates much of the sequence data found in GenBank. In 
addition to DNA sequence data, genomic studies generate data relating to the association between 
particular genetic markers and disease risk and other physiological traits. This type of data, which 
is more complex to record, search and correlate than raw sequence data, is stored in databases such 
as NLM’s Database of Genotypes and Phenotypes (dbGaP).   
 
Bermuda and the Origins of Rapid Genomic Data Release (1996) 
In the 1980s, U.S. science funding agencies began to require that researchers working on 
federally-funded projects release the data generated by their research to the public 6-12 months 
after collection, or at the latest when associated results were published in the literature (generally 
12-24 months after data collection).2 Along these lines, when the HGP was first organized, NIH 
	
1 For an overview of different genomic data resources comprising the “genomic commons”, see Jorge L. Contreras & 
Bartha M. Knoppers, The Genomic Commons, 19 ANNUAL REV. GENOMICS & HUMAN GENETICS 429 (2018). 
2 See, e.g., National Academies of Science, Ensuring the Integrity, Accessibility, and Stewardship of Research Data 
in the Digital Age 64 (2009); National Research Council, Sharing Publication-Related Data And Materials: 
Responsibilities Of Authorship In The Life Sciences 75 (2003); National Research Council, Bits Of Power – Issues 
In Global Access To Scientific Data 80–82 (1997). 
Electronic copy available at: https://ssrn.com/abstract=3692635
Contreras Genomic Data Release  2	
and DOE developed formal guidelines for the sharing of HGP data.3 These guidelines required 
that data generated by the HGP be deposited in GenBank, making it available to all scientists 
worldwide within six months after generation.  
In 1996 the HGP’s sequencing of the human genome was scheduled to begin. That year, 
approximately fifty HGP project leaders from around the world met in Hamilton, Bermuda to 
deliberate over the speed with which HGP data should be released to the public, and whether the 
6-month "holding period" approved in 1992 should continue.4 The resulting “Bermuda Principles” 
established that all DNA sequence information from large-scale human genomic sequencing 
projects should be "freely available and in the public domain in order to encourage research and 
development and to maximize its benefit to society."5 Specifically, the Bermuda Principles require 
that all human genomic sequence assemblies greater than one kilobase (Kb) in length be released 
within twenty-four hours after assembly, and that finished annotated sequences should be 
submitted immediately to a public database. 
The Bermuda Principles were revolutionary in that they established, for the first time, that 
data from public genomic projects should be released to the public almost immediately after their 
generation.  While this requirement seemed radical at first, it has since become ingrained as part 
of NIH’s basic position treating genomic data as a public good that should be widely available and 
unencumbered.6 
 
Genomic Data Release Post-HGP: The Ft. Lauderdale Principles (2003) 
Initial drafts of the human genome sequence were published by the HGP and Celera 
Genomics, a competing private effort, in 2001, and the full human genome sequence was finalized 
by the HGP in 2003.7 That year, the Wellcome Trust convened a meeting in Ft. Lauderdale, Florida 
to revisit rapid data release issues in the “post-genome” world.8 While the Ft. Lauderdale 
participants “enthusiastically reaffirmed” the 1996 Bermuda Principles, they also expressed 
concern over the inability of data generating scientists to study their results and publish analyses 
prior to the public release of data. The most significant outcome of the Ft. Lauderdale meeting was 
a consensus that the Bermuda Principles should apply to each “community resource project” 
(CRP), meaning “a research project specifically devised and implemented to create a set of data, 
reagents or other material whose primary utility will be as a resource for the broad scientific 
	
3NIH, DOE Guidelines Encourage Sharing of Data, Resources, HUMAN GENOME NEWS (Oak Ridge Nat’l Laboratory, 
Oak Ridge, Ten.), Jan. 1993, at 4. 
4 International Large-Scale Sequencing Meeting, HUMAN GENOME NEWS (Oak Ridge Nat’l Laboratory, Oak Ridge, 
Ten.), Apr.-June 1996, at 19. 
5 Summary of Principles Agreed at the First International Strategy Meeting on Human Genome Sequencing, U.S. 
DEPARTMENT OF ENERGY GENOME PROGRAM, 
http://www.ornl.gov/sci/techresources/Human_Genome/research/bermuda.shtml. 
6 For a comprehensive history of the Bermuda Principles and their impact on genomic science, see Katherine Maxson 
Jones, Rachel A. Ankeny, Robert Cook-Deegan, The Bermuda Triangle: The Pragmatics, Policies, and Principles for 
Data Sharing in the History of the Human Genome Project, 51 J. HIST. BIOLOGY 693 (2018). For the Bermuda 
Principles’ impact on patenting human genetic material, see Jorge L. Contreras, Bermuda’s Legacy: Patents, Policy 
and the Design of the Genome Commons, 12 MINNESOTA J. L., SCI. AND TECH. 61 (2011). 
7 See, generally, Francis Collins, Opinion: Has the Revolution Arrived?, 464 NATURE 674 (2010). 
8 Report of Meeting organized by the Wellcome Trust, Sharing Data from Large-Scale Biological Research Projects: 
A System of Tripartite Responsibility (Jan. 14–15, 2003), available at 
http://www.genome.gov/Pages/Research/WellcomeReport0303.pdf.  
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community.”  Under this definition, the twenty-four hour rapid release rules of Bermuda would be 
applicable to large-scale projects generating non-human sequence data, other basic genomic data 
maps, and other collections of complex biological data such as protein structures and gene 
expression information. In order to effectuate this data release requirement, funding agencies were 
urged to designate appropriate efforts as CRPs and to require, as a condition of funding, that rapid, 
pre-publication data release be required in such projects. 
Notwithstanding this show of support, the Ft. Lauderdale participants acknowledged that 
rapid, pre-publication data release might not be feasible or desirable in all situations, particularly 
for projects other than CRPs. In particular, the notion of a CRP, the primary goal of which is to 
generate a particular data set for general scientific use, is often distinguished from “hypothesis-
driven” research, in which the investigators’ primary goal is to solve a particular scientific 
question, such as the function of a specific gene or the cause of a specific disease or condition.9 In 
hypothesis-driven research, success is often measured by the degree to which a scientific question 
is answered rather than the completion of a quantifiable data set. Thus, the early release of data 
generated by such projects would generally be resisted by the data generating scientists who 
carefully selected their experiments to test as yet unpublished theories. Giving such data away 
before their theories are published could potentially enable a competing group to “scoop” the 
originating group, a persistent fear among highly competitive scientists. 
 
The NIH GWAS Policy and dbGaP (2007) 
 Following the completion of the HGP, researchers began to conduct large-scale studies 
seeking to associate particular sets of genetic markers with disease risk and other physiological 
traits (genome-wide association studies or GWAS). GWAS data, which necessarily includes 
phenotypic and clinical data in addition to genomic data, is more complex to record, search and 
correlate than raw sequence data, is stored in databases such as NLM’s Database of Genotypes 
and Phenotypes (dbGaP).  In response to the growing number of GWAS being conducted and the 
large amount of data generated by such studies, in August 2007 the NIH released a new policy 
regarding the generation, protection and sharing of data generated by all federally-funded GWA 
studies.10   
 The NIH GWAS Policy requires that researchers submit data collected from GWA studies 
to dbGaP, maintained by the NLM. In addition to genomic data, dbGaP can also accommodate 
phenotypic data, which includes elements such as de-identified subject age, ethnicity, weight, 
demographics, drug exposure, disease state, and behavioral factors, as well as study documentation 
and statistical results, including linkage and association analyses. Given the potential sensitivity 
of phenotypic data, dbGaP allows access to data on two levels: open and controlled. Open data 
access is available to the general public via the Internet and includes non-sensitive summary data, 
generally in aggregated form.  Data from the controlled portion of the database may be accessed 
	
9 Jane Kaye, et al., Data Sharing in Genomics – Re-shaping Scientific Practice, 10 NATURE REV. GENETICS 331, 332 
box 1 (2009).  
10 Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies (GWAS), 
72 Fed. Reg. 49290, 49294–97 (Aug. 28, 2007) (hereinafter “NIH GWAS Policy”); Modifications to Genome-Wide 
Association Studies (GWAS) Data Access, NAT’L INST. OF HEALTH (Aug. 28, 2008) (hereinafter “GWAS 
Amendment”).  
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only under conditions specified by the data supplier, often requiring certification of the user’s 
identity and research purpose. 
 The 2007 policy requires that researchers deposit descriptive information about each GWA 
study for inclusion in the “open access” portion of dbGaP. Researchers are also “strongly 
encouraged” to submit study results, including phenotypic, exposure and genotypic data, for 
inclusion in the “controlled access” portion of the database “as soon as quality control procedures 
have been completed.”11   
One of the principal concerns with GWAS data was the risk that phenotypic or clinical 
information could eventually be traced back to individuals.12 To address this concern, the NIH 
GWAS Policy requires that GWAS data be de-identified in accordance with HIPAA guidelines.13 
Moreover, the data in the controlled-access portion of dbGaP may be released only after approval 
of the proposed research use by a Data Access Committee (DAC),14 and then only under a signed 
Data Use Certification. The Data Use Certification requires researchers and their institutions to 
agree, among other things, to use data only for the approved research purpose, to protect data 
confidentiality, to implement appropriate data security measures, not attempt to identify individual 
data subjects, not to sell any data, not to share data with third parties, and to report violations to 
the DAC. Finally, the GWAS Policy states NIH’s position that a request under the Federal 
Freedom of Information Act (FOIA)15 for the release of individually-identifiable GWAS data 
would constitute an “invasion of personal privacy”, and will be denied.16 
The NIH GWAS Policy was amended in August, 2008, following the publication of a 
scientific paper demonstrating that inferences regarding individual identity could be made using 
statistical techniques.17 Due to concerns relating to potential identification of GWAS subjects, NIH 
withdrew certain GWAS-generated SNP data from the publicly-accessible portions of dbGaP and 
certain NCI databases and placed them in the controlled-access portions of these databases.18  
The NIH GWAS Policy addresses the publication priority concerns of data generators by 
stating an expectation that users of GWAS data refrain from submitting their analyses and 
conclusions for publication, or otherwise presenting them publicly, during an “exclusivity” period 
of up to twelve months from the date that the data set is made available. NIH also expresses a 
“hope” and expectation that “genotype-phenotype associations identified through NIH-supported 
and NIH-maintained GWAS datasets and their obvious implications will remain available to all 
investigators, unencumbered by intellectual property claims.”19 It goes on to explain that “[t]he 
filing of patent applications and/or the enforcement of resultant patents in a manner that might 
restrict use of NIH-supported genotype-phenotype data could diminish the potential public 
benefit they could provide.”20 However, in an effort to show some support for patent seekers, 
	
11 NIH GWAS Policy, supra note 10, at 49295.   
12 Id. at 49292. 
13 Id. at 49295. 
14 Id. at 49296. 
15 Federal Freedom of Information Act, 5 U.S.C. § 552 (2006). 
16 FOIA Exemption 6, 5 U.S.C. §552(b)(6). 
17 GWAS Amendment, supra note 10; Nils Homer et al., Resolving Individuals Contributing Trace Amounts of DNA 
to Highly Complex Mixtures Using High-Density SNP Genotyping Microarrays, PLOS GENETICS (Aug. 2008). 
18 GWAS Amendment, supra note 10.  
19 NIH GWAS Policy, supra note 10, at 49296. 
20 Id. at 49297 
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the GWAS Policy also “encourages patenting of technology suitable for subsequent private 
investment that may lead to the development of products that address public needs.”21 
 
Project-Specific Genomic Data Release Policies 
 In the years following the Ft. Lauderdale meeting, numerous large-scale genomic research 
projects were launched with increasingly sophisticated requirements regarding data release. These 
policies implement their requirements through contractual mechanisms that are more tailored and 
comprehensive than the broad policy statements of the HGP era. Moreover, improvements in 
database technology enabled the provision of differentiated levels of data access, the screening of 
user applications for data access, and improved tracking of data access and users. 
 In addition, the proliferation of genomic databases and research projects funded by NIH 
expanded the role of NIH’s NCBI in genomic research.  Rather than acting as a passive funder of 
genomic research, NIH and its sub-institutes have taken an increasingly active role in the 
development, curation and dissemination of data created through NIH-funded research.22 
 
Genetic Association Information Network (GAIN) (2006) 
The Genetic Association Information Network (GAIN) was established in 2006 by the 
Foundation for the National Institutes of Health (FNIH), the NIH and several corporations.23 
GAIN’s purpose was to conduct GWA studies of the genetic basis for six common diseases. Data 
generators in the GAIN program were required to sign an applicant agreement agreeing to various 
program commitments, including “immediate” release of data generated by the project.24 Over the 
course of the three-year project, approximately 18,000 human DNA samples were genotyped.25 
The resulting data was deposited in dbGaP. Researchers wishing to access data from the controlled 
portion of the database were required to register with, and be approved by, the GAIN Data Access 
Committee (DAC).26  
 Perhaps most importantly, the GAIN policy was the first U.S. Federal genomic data release 
policy to introduce a temporal restriction on the users of the data (as opposed to the temporal 
release requirements imposed on data generators by the Bermuda Principles). That is, in order to 
secure a period of exclusive use and publication priority for the data generators, data users were 
prohibited from submitting abstracts and publications and making presentations based on GAIN 
data for a specified embargo period.27 The duration of the embargo period for a given data set is 
	
21 Id. at 49296. 
22 See Jorge L. Contreras, Leviathan in the Commons: Biomedical Data and the State, in GOVERNING MEDICAL 
KNOWLEDGE COMMONS, Ch. 2 (Katherine Strandburg, Brett Frischmann, Michael Madison eds., Cambridge Univ. 
Press: 2017). 
23 See generally The GAIN Collaborative Research Group, New models of collaboration in genome-wide association 
studies: the Genetic Association Information Network, 39 NATURE GENETICS 1045 (2007) [hereinafter GAIN 
Consortium].   
24 GAIN Consortium, supra note 23, at 1048 (Box 1). 
25 Teri A. Manolio, Collaborative genome-wide association studies of diverse diseases: programs of the NHGRI’s 
office of population genomics, 10 PHARMACOGENOMICS 235, 236 (2009). 
26 GAIN Consortium, supra note 23, at 1049. 
27 Id. 
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identified in the relevant data repository and may vary by data set, but has generally been set at 
nine months.28 
  
The Cancer Genome Atlas (TCGA) (2006) 
In 2006, the National Cancer Institute (NCI) and NHGRI launched a project to catalog 
genomic changes relating to cancer.29 The Cancer Genome Atlas (TCGA) project generated 
genomic sequence and related data for cancer tumor cells, but also kept track of a large amount of 
clinical data, including patient diagnosis, treatment history and ongoing status. Due to the 
specialized nature of the project data, deposits were made both in dbGaP as well as a TCGA-
specific database administered by NCI.  Given the potential for identifying individual patients from 
their genomic and phenotypic data, attention was paid to controlling access to TCGA data. TCGA 
data is available in an open-access tier and a controlled-access tier similarly to dbGaP.30 Open-
access is provided for data that cannot be aggregated to generate an individually-identifiable 
dataset, whereas controlled-access enables researchers to access clinical and individually-unique 
data. Access to the controlled-access data tier requires the user’s acknowledgement of a Data 
Access Certification containing restrictions on research use, security, transferability and other 
matters. 
 
ENCODE and modENCODE (2007) 
In 2007 NIH launched the ENCODE and modENCODE projects to identify functional 
genomic elements in humans and two model organisms.31 The ENCODE data release policy32 
designates the project as a “community resource project”, but also recommends a nine-month 
embargo period during which users of released data are requested not to publish or present results 
based on that data.  The ENCODE Policy distinguishes between published and unpublished data, 
verified and unverified data, and offers several examples of the data use implications for different 
types of studies. The length and complexity of the policy evidences the agency’s and the 
participants’ desire for clear guidelines and the avoidance of misunderstandings regarding the 
release of data, as the diversity of participants, organisms and data types had expanded 
dramatically beyond those originally considered by the framers of the Bermuda Principles.  
 
The Human Microbiome Project (2008) 
The Human Microbiome Project (HMP) was a large-scale community resource project 
initiated in 2008 that was designed to identify and sequence the genomes of selected 
microorganisms inhabiting the human body.33 While much HMP data was subject to rapid 
	
28 Id.  
29 Francis S. Collins & Anna D. Barker, Mapping the Cancer Genome, SCI. AM., Mar. 2007, at 50.  
30 Data Access, THE CANCER GENOME ATLAS DATA PORTAL, http://cancergenome.nih.gov/dataportal/data/access/. 
31 Susan E. Celniker et al., Unlocking the Secrets of the Genome, 459 NATURE 927 (2009). 
32 ENCODE Consortia, DATA RELEASE, DATA USE, AND PUBLICATION POLICIES (2008), available at 
http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf.  
33 Peter J. Turnbaugh, et al., The Human Microbiome Project, 449 NATURE 804 (2007); Human Microbiome Project 
Awards Funds for Technology Development, Data Analysis and Ethical Research, NIH NEWS (Oct. 7, 2008), 
http://www.genome.gov/27528386. 
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Bermuda-like disclosure requirements, investigators were permitted to withhold certain other data 
from the public for a period of several months.34 This hold-back period was intended to permit 
HMP researchers to analyze and prepare publications on their data before it is released to 
competing researchers. The reasons that researchers, who are often driven by intense competitive 
pressure to publish and claim credit for discoveries, pushed for such hold-back periods is clear.  
However, it also appears, at least in the case of HMP, that NIH did not vigorously advance the 
patent deterrent arguments that previously motivated policy decisions during the HGP and its 
immediate aftermath. 
 
Data Release Policies Beyond Genomics 
The success and broad adoption of genomics data release policies incorporating the 
Bermuda and Ft. Lauderdale Principles have led scientists in related fields to consider the adoption 
of analogous principles in their own research.  One prominent example occurred in 2008, when 
the National Cancer Institute convened a meeting of proteomics researchers in Amsterdam to 
“identify and address potential roadblocks to rapid and open access to [proteomics] data.”35 
Participants identified technical, infrastructure and policy challenges to the rapid release of 
proteomic data. Technical challenges included the wide variety of disparate platforms and 
techniques used to generate proteomic data, making “raw” data from experimental instruments 
difficult to interpret by scientists unfamiliar with, or lacking access to, the instruments used to 
generate the data. Proteomics also lacks the established public database infrastructure of genomics. 
Whereas DNA sequence data can be deposited readily in GenBank, the EMBL or DDBJ, and is 
often deposited in all three, there is no common public data repository for proteomic data, and 
existing proteomic databases suffer from inconsistent and sometimes incompatible data formats. 
Finally, unlike genomics, in which the entire field focused for several years on the single HGP 
project, proteomics research lacks a unifying policy core and proteomics-focused journals have 
each developed their own, sometimes inconsistent, guidelines for data submission. 
Notwithstanding these difficulties, the Amsterdam participants articulated six data release 
and sharing principles that reflect the spirit of the Bermuda and Ft. Lauderdale Principles: (1) 
Timing (should depend on the nature of the effort generating the data, but should in no event be 
later than publication or, for community resource projects, following appropriate quality assurance 
procedures), (2) Comprehensiveness (full raw data sets should be released together with associated 
metadata and quality data), (3) Format (standardized formats are encouraged), (4) Deposition to 
repositories (central repositories for proteomic data should be established), (5) Quality metrics 
(central repositories should develop metrics for assessing data quality), and (6) Responsibility 
(scientists, funding agencies and journals share responsibility for ensuring adherence to 
community data release standards). 
In 2009, more than one hundred scientists, journal editors, legal scholars and 
representatives of governmental and private funding agencies met in Toronto to assess the current 
state of rapid pre-publication data release and the applicability of the Bermuda Principles in 
	
34 HMP Data Release and Resource Sharing Guidelines for Human Microbiome Project Data Production Grants, 
NIH COMMON FUND, http://commonfund.nih.gov/hmp/datareleaseguidelines.asp. 
35 Henry Rodriguez et al., Recommendations From the 2008 International Summit on Proteomics Data Release and 
Sharing Policy:  A Summit Report, 8 J. PROTEOMICS RES. 3689 (2009). 
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projects well beyond the generation of genomic sequence data.36 The participants reaffirmed a 
general community commitment to rapid pre-publication data release, expanding the scope of 
projects as to which these principles should apply to all biomedical datasets having “broad utility, 
are large in scale … and are ‘reference’ in character”. Specifically, they cited, in addition to 
genomic and proteomic studies, structural chemistry, metabolomics and RNAi datasets as well as 
annotated clinical resources such as cohorts, tissue banks and case-control studies. 
The expansion of rapid pre-publication data release principles beyond genomics and 
proteomics projects, which often have as their ultimate goal the generation of a large data set, to 
these other areas necessarily raises issues concerning the appropriateness of rapid data release in 
hypothesis-driven research. Accordingly, the Toronto participants concurred that, while funding 
agencies should require rapid pre-publication data release for “broad utility” projects, rapid data 
release “should not be mandated” for projects that are generally hypothesis-driven. The Toronto 
participants also addressed the priority concerns of data generators versus data users, observing 
anecdotally that in many cases data users have, in fact, published papers based on publicly-released 
data sets before the publication of the data generators’ papers analyzing the data sets themselves, 
and that this situation caused no “serious damage” to the data generators’ subsequent publications. 
Nevertheless, the participants acknowledged the acceptability of a “protected period” during which 
data users could be restricted from publishing on released data sets, cautioning, however, that this 
period should never exceed one year. The Toronto participants produced a set of “best practices” 
embodying these principles and applying them to the three constituencies originally identified in 
Ft. Lauderdale – funding agencies, data generators and data users – as well as to scientific journals, 
which were urged to monitor and provide guidance relating to data release issues. 
 
Obama Administration Directives On Federal Data Sharing 
In February 2013, John Holdren, Director of the White House Office of Science and 
Technology Policy (OSTP) issued a memorandum directing Federal agencies with annual R&D 
budgets of more than $100 million to develop plans for increasing public access to the results of 
research that they fund.37 The Memorandum recognized that “making research results accessible 
to the largest possible audience – other researchers, business innovators, entrepreneurs, teachers, 
students, and the general public – can boost the returns from Federal investments in R&D. 
Increased access expands opportunities for new scientific knowledge to be applied to areas as 
diverse as health, energy, environmental protection, agriculture, and national security and to 
catalyze innovative breakthroughs that drive economic growth and prosperity.”   
In May 2013, President Obama issued Executive Order 13642, "Making Open and Machine 
Readable the New Default for Government Information,”38 which required that data generated or 
funded by Federal agencies be made available in open, machine-readable formats while 
appropriately safeguarding privacy, confidentiality, and security. Shortly thereafter, the White 
House Office of Management and Budget (OMB) issued a new Federal Open Data Policy (M-13-
	
36 Toronto International Data Release Workshop Authors, Prepublication Data Sharing, 461 Nature 168 (2009). 
37 https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/ostp_public_access_memo_2013.pdf 
38 White House Executive Order 13642, "Making Open and Machine Readable the New Default for Government 
Information,  
https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/ostp_public_access_memo_2013.pdf 
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13)39 that designated data as a valuable national resource and strategic asset. The Federal Open 
Data Policy requires that Federal agencies make data and information open in machine-readable 
format in order to "accelerate scientific breakthroughs and innovation, promote entrepreneurship, 
and enhance economic growth and job creation."    
 
NIH’s Fourth Generation Data Sharing Policies 
The Genomic Data Sharing (GDS) Policy (2014) 
 In 2014, responding to the OMB’s 2013 directive, NIH released a new Genomic Data 
Sharing (GDS) policy. The GDS policy expanded the scope of the 2007 GWAS policy in several 
important respects. Whereas the GWAS policy covered only human GWAS data, the GDS Policy 
covers all large-scale human and non-human genomic data.  This comprehensive scope unifies 
NIH’s approach to different data types across its many institutes. The GDS policy also requires, 
among other things, that human subjects provide informed consent to the broad sharing and 
research use of data generated using their DNA, a requirement that is likely to result in significant 
debate and to require further clarification from NIH as it is implemented.  
Under the GDS policy, human genomic data must be submitted to NIH promptly following 
cleaning and quality control (generally within three months after generation).  Once submitted, 
this data may be retained by NIH for up to six months prior to public release.  Non-human and 
model organism data, on the other hand, can be retained by data producers until their initial 
analyses of the data are published, representing a much longer lead time.  In both cases, once 
released, data is not subject to further embargoes or restrictions on analysis or publication.  The 
GDS policy thus diverges from the GWAS and other contemporary policies in that it (a) permits 
the withholding of data from the public for a fixed period of time, and (b) does not utilize 
embargoes on data usage following its release.40 
 
The Cancer Moonshot Public Access and Data Sharing (PADS) Policy (2017) 
In 2016, the National Cancer Institute (NCI), the largest research funding organization 
within NIH, launched an ambitious $1.8 billion research program directed at accelerating cancer 
research – the Cancer Moonshot Program. In 2017, the Cancer Moonshot Program adopted a new 
Public Access and Data Sharing (PADS) Policy to encourage the broad sharing of data and 
publications among researchers and the public.41 
The Policy addresses both open access to publications resulting from Cancer Moonshot-
funded research as well as the release of data generated by that research.42 With regard to data, the 
	
39 Exec. Off. Pres., Off. Mgt. & Budget, Open Data Policy-Managing Information as an Asset, Memorandum M-13-
13, May 9 2013, https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/memoranda/2013/m-13-13.pdf 
40 For a discussion and critique of these changes, see Jorge L. Contreras, NIH’s Genomic Data Sharing Policy:  Timing 
and Tradeoffs, 31 TRENDS IN GENETICS 55 (2015). 
41 National Cancer Institute (NCI) (2017a). NCI Cancer Moonshot Public Access and Data Sharing Policy (Aug. 4, 
2017). 
42 Release of scientific publications is beyond the scope of this paper. For a discussion of NIH’s open access 
publication requirements, see, e.g., Jorge L. Contreras, Confronting the Crisis in Scientific Publishing: Latency, 
Licensing and Access, 53 SANTA CLARA L. REV. 491 (2013); Tammy M. Frisby & Jorge L. Contreras, The NCI Cancer 
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PADS Policy states that “to the extent feasible,” data should be made publicly available 
simultaneously with the publication of research results. Unlike prior NIH data sharing policies that 
pertained primarily to genomic and related data, the PADS Policy defines data that must be shared 
as any “recorded factual material commonly accepted in the scientific community as necessary to 
document and support research findings in Publications”. This broad definition thus encompasses 
all forms of clinical, pharmacological, demographic, analytical, survey, and other data that might 
be collected or developed as part of a Cancer Moonshot project.  
Because the scope of covered data is so broad, NCI offers applicants for Cancer Moonshot 
funding a degree of flexibility in deciding how to release their research results and data. Thus, the 
only firm requirement of the PADS policy is that applicants submit to NCI a written plan that 
describes a proposed process for making data “immediately and broadly available to the public” 
and, if such sharing is not possible, a justification for why it is not. NCI emphasizes that its review 
of grant funding proposals “will give funding priority to those Applicants that submit an 
appropriate [PADS] [p]lan that ensures maximal sharing of [publications and data] arising from 
the award.” Despite its ambitious goals, one recent study has found that few submitted PADS plans 
during the first year that the PADS policy was in effect conformed to its requirements.43 
 
NIH’s Draft Policy for Data Management and Sharing (DMS) (2019) 
In 2015, NIH began planning a more sweeping overhaul of its trans-institute data sharing 
program (NIH, 2015). In November, 2019, it released a draft Policy for Data Management and 
Sharing (DMS) for public comment.44 Like the Cancer Moonshot PADS Policy, the draft DMS 
policy mandates that researchers seeking NIH funding submit a data sharing plan as part of their 
grant applications. This plan would be reviewed by the funding agency in evaluating the 
application, and compliance would be monitored during the course of the funded research program. 
A final DMS policy has not been released as of this writing. 
 
OPEN Government Data Act (2019) 
In January 2019, the U.S. Congress enacted the Open, Public, Electronic, and Necessary 
(OPEN) Government Data Act,45 codifying the open data principles contained in the OSTP, OMB 
and Executive memoranda of 2013. Among other things, the OPEN Government Data Act requires 
Federal agencies to publish data arising from Federal research online using standardized, machine-
readable data formats, with metadata uploaded to the Data.gov catalog, and to prepare inventories 
of their available datasets. 
 
	
Moonshot Public Access and Data Sharing (PADS) Policy – Initial Assessment and Implications, 2 DATA & POLICY 
E9 (2020). 
43 See Frisby & Contreras, supra note 42. 
44 National Institutes of Health (NIH). Request for Public Comments on a DRAFT NIH Policy for Data Management 
and Sharing and Supplemental DRAFT Guidance. 84 Fed. Reg. 60398 (Nov. 8, 2019). 
45 P.L. 115-435, 132 Stat. 5529 (Jan. 14, 2019) (Title II of the Foundations for Evidence-Based Policymaking Act of 
2018). 
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Conclusion 
 The forward-looking genomic data release policies developed by the HGP a quarter century 
ago have shaped the landscape of scientific data release both in the U.S. and around the world.46  
Today, data sharing from government-funded scientific projects is not limited to the field of 
genomics, but it is a Federal statutory requirement for data arising from all scientific fields of 
inquiry from astronomy to geology to biochemistry to psychology.  Yet despite the endorsement 
of data sharing principles at the highest levels of the United States government, it is not clear that 
researchers in all scientific fields are prepared to embrace rapid and public data sharing as Federal 
policy requires. The priority and publication concerns of data-generating researchers are still very 
real, particularly in fields outside of genomics,47 and as a recent study of the latest NCI data sharing 
policy shows, there may be a lack of understanding of data sharing practices and principles even 
in related biomedical research fields.48 Thus, despite Federal policy on the books, additional 
training, education and socialization of data sharing norms within the broader scientific community 
must continue in order to realize the full potential of this key element of open science. 
 
	
46 See, generally, Contreras & Knoppers, supra note 1, Yann Joly et al., Open science and community norms: Data 
retention and publication moratoria policies in genomics projects, 12 MEDICAL L. INTL. 92 (2014). 
47 See Rudolf I. Amann, et al., Toward unrestricted use of public genomic data, 363 SCIENCE 350 (2019). 
48 See Frisby & Contreras, supra note 42. 
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